Reports 1H24 $316,000 vs. $392,000 last year. “With two drugs in advanced clinical studies we continue to enroll patients and push forward towards a positive conclusion of each program. We continue to position our drugs for multi-billion markets with unmet needs,” stated Can-Fite CEO & CFO Motti Farbstein.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
- Is CANF a Buy, Before Earnings?
- Can-Fite BioPharma Proposes Warrant Exercise Incentives
- Can-Fite BioPharma Raises $5 Million
- Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds